Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic - IBS News, Media, Research Results, Discussion or Abstracts - IBS Self Help and Support Group Forums -

Jump to content

- - - - -

Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic

Aliva prebiotic probiotic

  • Please log in to reply
1 reply to this topic

#1 Jeffrey Roberts

Jeffrey Roberts

    Member #1 Founder

  • Retired
  • PipPipPipPip
  • 7295 posts
  • Country:United States

Posted 08 September 2014 - 10:23 AM


Journal World Journal of Gastroenterology

Manuscript Type Randomized Controlled Trial 1.gif    

Manuscript Number 7470 1.gif    

Manuscript Title Resolution of acute gastroenteritis symptoms in children and adults treated with a novel polyphenol-based prebiotic     

All Authors Telma Noguera, Robert Wotring, Chris R Melville, Kara Hargraves, Jochen Kumm, John M Morton     

Manuscript Source   1.gif    

Submit User Robert G Wotring 1.gif    

Correspondence to John M. Morton, MD, MPH Stanford Digestive Health Center, 145 Tasso St, Palo Alto, CA 94301 [email protected] 1.gif    

Article Scope Clinical Practice 1.gif    

Specialty Type Gastroenterology and Hepatology 1.gif    

Keywords Gastroenteritis,Prebiotic,Polyphenol,Diarrhea,Acute 1.gif    

Core Tip The global standard of care for treating acute gastroenteritis in children is 5-10 days of oral rehydration therapy, which saves lives and may reduces the duration of the illness by 20%. In this double-blind, placebo-controlled clinical study, 60% and 89% of subjects receiving a novel polyphenol-based prebiotic experienced their last unformed stool within two hours, and 24 hrs, respectively. This represents an extraordinary advance in the clinical management of acute gastroenteritis. If other research sites are able to repeat these results with different populations, they should become the new global standard of care.     


Abstract Introduction: Acute gastroenteritis is a prevalent disease with persistent morbidity and mortality. Acute gastroenteritis has multiple causative agents. Current treatment methods are essentially supportive in nature with oral rehydration widely considered to be the primary treatment. The role of polyphenols-based prebiotics in treating acute gastroenteritis has not been examined to date. Methods: A two-arm randomized, double-blinded, placebo-controlled clinical study was conducted at two public health centers in Managua, Nicaragua. Potential subjects who qualified based on inclusion/exclusion criteria were randomly assigned to one of two treatment arms. Two thirds of the subjects (N=200) received 2 liquid ounces of a novel polyphenol-based prebiotic (AlivaTM) diluted in 8 ounces of oral rehydration solution (ORS). One third of the subjects (N=100) were randomized to receive 2 liquid ounces of a taste and color-matched placebo diluted in 8 ounces of ORS. The primary outcome variable measured the time to last unformed stool (TTLUS) after treatment. The secondary outcome variables measuring stomach discomfort; gas & bloating; and heartburn/indigestion were also determined. Results: The percentage of subjects recording their last unformed stool was lower for those who received Aliva vs. placebo at 30 minutes (P < 0.01), 2 hours (P < 0.001), 24 hours (P < 0.001), 72 hours (P < 0.001), and 5 days (P < 0.01). In addition, there were statistically significant improvements in self-reported secondary outcomes as early as 90 minutes after ingestion in the prebiotic vs. placebo treatment group. Conclusion: In this double-blind, randomized clinical study, subjects with acute gastroenteritis receiving Aliva showed significant improvement of multiple associated symptoms vs. those receiving placebo 1.gif    


Cover Letter We are pleased to present the remarkable results of our research for consideration in your esteemed journal. As you are likely aware, our corresponding author John M. Morton, M.D. of Stanford University, is a member of your editorial board and the president elect of the American Society of Metabolic and Bariatric Surgery. We are confident you'll find the results herein compelling and extraordinary. We look forward to receiving your feedback and look forward to the opportunity to address any questions you may have. Please feel free to reach out to me with questions via email at [email protected] or by phone at (650) 644-5377. Respectfully, Robert Wotring     


Manuscript 7470-Editted.pdf

#2 zeroblue


    Prolific Member

  • Members
  • PipPipPip
  • 225 posts
  • Country:Canada

Posted 12 September 2014 - 01:06 AM

I wonder if this also reduces the risk for IBS-PI

Also tagged with one or more of these keywords: Aliva, prebiotic, probiotic


About Us | Contact Us | Advertise With Us | Disclaimer | Terms of Service | Crisis Resources

Irritable Bowel Syndrome |  Inflammatory Bowel Disease |  Crohn's Disease |  Ulcerative Colitis |  Fibromyalgia |  GERD - Reflux Disease

©Copyright 1995-2016 IBS Self Help and Support Group All rights reserved

This website is certified by Health On the Net Foundation. Click to verify. We comply with the HONcode standard for trustworthy health information: verify here